secwatch / observer
8-K filed January 30, 2026, 6:59 PM ET ticker BCAB CIK 0001826892
other material confidence high sentiment negative materiality 0.85

BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk

BioAtla, Inc.

item 5.03item 5.07item 7.01item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-031942
form_type
8-K
ticker
BCAB
cik
0001826892
company_name
BioAtla, Inc.
filed_at
2026-01-30T23:59:59+00:00
discovered_at
2026-05-14T18:02:36.390615+00:00
generated_at
2026-05-16T06:04:00.640283+00:00
sec_items
["5.03", "5.07", "7.01", "8.01", "9.01"]
event_type
other_material
sentiment
negative
materiality_score
0.85
calibrated_materiality_score
0.85
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-031942
json_url
https://secwatch.observer/filing/0001193125-26-031942.json
markdown_url
https://secwatch.observer/filing/0001193125-26-031942.md
text_url
https://secwatch.observer/filing/0001193125-26-031942.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/0001193125-26-031942-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/bcab-20260126.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

93eb4ea69bfc9e1d968d0720e98791c0be1396d6

BioAtla, Inc.: Filed Certificate of Elimination to remove Series A Junior Preferred Stock from the Amended and Restated Certificate of Incorporation (effective 2026-01-30).

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

CWEN

Clearway Energy eliminates Class A stock; converts all shares to reduced-vote Class C

Clearway Energy, Inc. May 1, 2026, 7:59 PM ET other_material Items 1.01, 3.03, 5.03, 5.07, 7.01, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 7.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

Following the Class A Conversion, on May 1, 2026, the Company filed with the Delaware Secretary of State a certificate of retirement pursuant to Section 243 of the DGCL (the “Certificate of Retirement”) to retire all shares of Class A common stock converted in the Class A Conversion, which also had the effect of amending the Amended Charter to (i) reduce the total number of authorized shares of Class A common stock from 34,613,853 to zero, (ii) reduce the total number of authorized shares of capital stock of the Company from 2,544,613,853 to 2,510,000,000 and (iii) eliminate from the Amended Charter all references to the Class A common stock (collectively, the “Class A Retirement”).

Filing page SEC filing

DMAA

SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

Drugs Made In America Acquisition Corp. May 1, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

to amend the Company’s Second Amended and Restated Memorandum and Articles of Association (the “ Existing Charter ”) by adopting an amendment to the Existing Charter in the form set forth in Annex A to the Proxy Statement (the “ Extension Amendment ”) which reflects the extension of the date by which the Company must consummate a business combination (the “ Combination Period ”) up to twelve (12) times from April 29, 2026 (the “ Termination Date ”) to April 29, 2027, each by an additional one (1) month

Filing page SEC filing

BAFN

BayFirst raises $80M in PIPE, reports Q1 loss of $5.7M, names new bank CEO

BayFirst Financial Corp. April 30, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 2.02, 5.02, 7.01, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 7.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

On April 28, 2026, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Division of Corporations creating and authorizing 4,000 shares of Series D Preferred Stock and 4,000 shares of Series E Preferred Stock.

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

QLEP

Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE

Quantum Leap Acquisition Corp May 6, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.

Filing page SEC filing

MCAH

Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30

Mountain Crest Acquisition 6 Corp. May 5, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.

Filing page SEC filing

MRKR

Marker Therapeutics shareholders approve increase in authorized shares from 30M to 130M

Marker Therapeutics, Inc. May 4, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 9.01 same event type: other_material similar materiality

This filing

On January 30, 2026, BioAtla, Inc. (the “Company” or “BioAtla”) filed a Certificate of Elimination (the “Certificate of Elimination”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A Junior Preferred Stock, par value $0.0001 per share (the “Series A Junior Preferred Stock”), following the redemption of the one (1) issued and outstanding share of Series A Junior Preferred Stock (the “Series A Preferred Share”).

Comparable filing

the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock (the “ Charter Amendment ”).

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-031942
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.